Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, on the basis of the crystal structure of K-Ras, 21 analogues (TKR01-TKR21) containing urea or thiourea were rationally designed, which can effectively inhibit the lung cancer cell A549 growth.
|
31851852 |
2020 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Despite substantial progress in lung cancer immunotherapy, the overall response rate in KRAS-mutant lung adenocarcinoma (ADC) patients remains low.
|
31744829 |
2020 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A total of 1271 small molecules were screened in KRAS-mutant and wild-type lung cancer cell lines.
|
30862488 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activated KRAS is frequently observed and paralleled by inactivating of tumor suppressors in lung cancer, while the mechanisms remained elusive.
|
30906631 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we show that long-term supplementation with the antioxidants N-acetylcysteine and vitamin E promotes KRAS-driven lung cancer metastasis.
|
31257027 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Combined mTOR, IGF1R, and MEK inhibition inhibits the principal signaling pathways required for the survival of KRAS-mutant cells and produces marked tumor regression in three different KRAS-driven lung cancer mouse models.
|
31534020 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Except for the detection of ERBB2 amplification and KRAS mutation in two patients, no other classic lung cancer driver mutations were detected.
|
31659278 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To begin with, we developed a pipeline to utilize a set of computational tools in order to obtain the most deleterious nsSNPs (Q22K, Q61P, and Q61R) associated with lung cancer in the human KRAS gene.
|
31117243 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings demonstrate that the miR-148a-3p may play a significant role in NSCLC including the kind of lung cancer with K-Ras gene mutation, and it exerted the tumor inhibitor function by targeting SOS2.
|
30536836 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations may act as a resistance mechanism to MET inhibition in MET dependent lung cancer.
|
31200822 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer cell lines with KRAS mutation were relatively more sensitive to KRA-533 than cell lines without KRAS mutation.
|
30971271 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the effects of the combination vary, the combined therapeutics are one of the best options at present to treat KRAS mutant lung cancer.
|
31475900 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Since mutated KRAS has been implicated in the development of various cancers including lung cancer, we tested a mutant-allele specific siRNA against KRAS<sup>G12S</sup>, in A549 cells.
|
30771430 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we show that genetic inhibition of SHOC2 suppresses tumorigenic growth in a subset of KRAS-mutant NSCLC cell lines and prominently inhibits tumour development in autochthonous murine KRAS-driven lung cancer models.
|
31182717 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Collectively, these results uncover collateral vulnerabilities co-occurring with drug resistance and tumor heterogeneity, informing novel therapeutic avenues for KRAS-mutant lung cancer.
|
31431614 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
|
30833304 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our study shows that TTF-1 sensitizes the KRAS-mutated A549 and NCI-H460 lung cancer cells to cisplatin, a common chemotherapy used to treat lung cancer.
|
31142791 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We performed genome-scale loss-of-function CRISPR-Cas9 screens in the presence of a MEK1/2 inhibitor (MEKi) in KRAS-mutant pancreatic and lung cancer cell lines and identified genes that cooperate with MEK inhibition.
|
31577942 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The impact of EGFR and KRAS mutations in Brazilian lung cancer remains poorly explored.
|
30824880 |
2019 |
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results pinpoint mTOR as a mechanism of resistance to chemotherapy in KRAS-mutant lung cancer and validate a rational and readily translatable strategy that combines mTOR inhibitors with standard chemotherapy to treat KRAS-mutant adenocarcinoma, the most common and deadliest lung cancer subset.
|
30171261 |
2019 |
Carcinoma of lung
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Together, our results suggest that mutant KRAS promotes RAD51 expression to enhance DNA damage repair and lung cancer cell survival, suggesting that RAD51 may be an effective therapeutic target to overcome chemo/radioresistance in KRAS mutant cancers.[BMB Reports 2019; 52(2): 151-156].
|
30638176 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results indicate that REG4 plays an important role in KRAS-driven lung cancer pathogenesis and is a novel biomarker of lung adenocarcinoma subtype.
|
31428934 |
2019 |
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken together, these results provide a novel mechanistic understanding of how the IKKβ pathway affects human lung tumorigenesis, indicating that IKKβ promotes KRAS-induced angiogenesis both by cancer cell-intrinsic and cancer cell-independent mechanisms, which strongly suggests IKKβ inhibition as a promising antiangiogenic approach to be explored for KRAS-induced lung cancer therapy.
|
30885340 |
2019 |